The role of CD36 receptor in the pathogenesis of atherosclerosis

Adv Clin Exp Med. 2017 Jul;26(4):717-722. doi: 10.17219/acem/62325.


Atherosclerosis is a progressive, chronic inflammation in artery walls. Oxidized low density lipoproteins (ox-LDL) play an important role in atherosclerotic plaque formation. ox-LDL are taken up by macrophages mainly through scavenger receptors, among which CD36 is considered to be the most important. Animal studies have shown that crossing atherogenic mice with a strain lacking the expression of CD36 prevented the development of atherosclerosis despite a diet rich in saturated LCFA. In humans, autopsy studies performed in obese patients have demonstrated increased expression of CD36 receptor on macrophages, comprised within atherosclerotic plaques. Until recently it had been believed that CD36 is a major player in atherosclerosis progression in humans. However, recent studies challenge this conviction, showing increased incidence of coronary heart disease in the subgroup of patients with decreased expression of CD36. This article reviews the role of CD36 receptor in the development of atherosclerosis. The authors also discuss current possibilities to interfere with CD36, their potential benefits and hazards.

Keywords: CD36 receptor; atherosclerosis; ox-LDL.

Publication types

  • Review

MeSH terms

  • Arginine / pharmacology
  • Atherosclerosis / etiology*
  • CD36 Antigens / chemistry
  • CD36 Antigens / genetics
  • CD36 Antigens / physiology*
  • Gene Expression Regulation
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Thiazolidinediones / pharmacology


  • CD36 Antigens
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Thiazolidinediones
  • Arginine
  • 2,4-thiazolidinedione